ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

ANZMTG 01.14 ABC Trial - A phase II study of nivolumab and nivolumab combined with ipilimumab in patients with melanoma brain metastases

Brain metastases are a common and serious complication of metastatic melanoma. Up to 50% of patients develop brain metastases during the course of their illness, and approximately 20% of patients have them at first presentation with metastatic disease. This is a Phase 2 study and will look to evaluate the effectiveness of nivolumab and nivolumab combined with ipilimumab in three patient cohorts: cohorts 1 and 3 are melanoma patients with brain metastases that have had no prior localised treatments and no neurological symptoms related to brain metastases, while cohort 2 are melanoma patients with brain metastases who have had a prior failed local therapy or have current neurological symptoms or have leptomeningeal disease

Study Status:
Active, not recruiting
Clinical Trials Registry number: ACTRN12614001315606
ClinicalTrials.gov identifier: NCT02374242

Principal Investigator:
Professor Georgina Long
Melanoma Institute Australia (MIA)

MIA Co-ordinator Details:
Email: ABCstudy@melanoma.org.au 
 
Documents (PDF downloads):


Return to Previous Page